Jemonda-S 10/100 Tablet contains a combination of Dapagliflozin (10 mg) and Sitagliptin (100 mg), indicated for the management of type 2 diabetes mellitus. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting urinary glucose excretion and thereby lowering blood glucose levels. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner. The combined action of these agents provides complementary mechanisms to improve glycemic control in patients inadequately controlled by diet and exercise alone. Jemonda-S 10/100 is typically administered once daily, with or without food, under medical supervision. It is essential to monitor renal function prior to and during therapy, as dose adjustments may be necessary in renal impairment. Common adverse effects include urinary tract infections, nasopharyngitis, and hypoglycemia, particularly when used with insulin or insulin secretagogues. Patients should be advised on signs of ketoacidosis and instructed to maintain adequate hydration. This combination therapy should be used cautiously in patients with a history of pancreatitis or hypersensitivity to its components. Jemonda-S 10/100 offers an effective option for optimizing glycemic control in type 2 diabetes management.